EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Progress of siRNA Nanomedicines in Modulating the Microenvironment of Triple-Negative Breast Cancer

Yongxuan Long, Hongyu Yin, Jinbo Li, Weijie Zhang

International Journal of Nanomedicine · 2026

DOI: 10.2147/ijn.s629428 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Nanomedicine, 2026. Verfasst von Yongxuan Long und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Breast Surgery, Department of General Surgery, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Na…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Tumor Microenvironment, RNA, Small Interfering, Nanomedicine. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype, and its poor prognosis, chemoresistance, and limited immunotherapy response are closely linked to pathological remodeling of the tumor microenvironment (TME). Targeting the TME has emerged as a promising strategy, but conventional agents such as monoclonal antibodies and small-molecule inhibitors are limited by undruggable targets, off-target toxicity, and poor tumor penetration. Small interfering RNA (siRNA) enables sequence-specific silencing of multiple TME-related genes-including TGF-β, PD-L1, and HIF-1α-offering a flexible approach to reverse immunosuppression, fibrosis, and hypoxia. However, poor in vivo stability and inefficient intratumoral delivery have hindered clinical translation. Recent advances in intelligent nanocarriers, including pH/enzyme-responsive and biomimetic membrane-coated systems, together with spatial omics-guided target selection, have substantially improved siRNA delivery and therapeutic efficacy. This review summarizes the immunoregulatory mechanisms and key targets within the TNBC microenvironment, the design principles and technological bottlenecks of siRNA nanodelivery systems, and emerging combination strategies with immune checkpoint inhibitors. It further discusses subtype-specific targeting needs, long-term resistance risks, and translational challenges from preclinical models to clinical applications, providing a systematic framework for siRNA nanomedicine-based remodeling of the TNBC microenvironment and highlighting critical directions for future precision combination therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsTumor MicroenvironmentRNA, Small InterferingNanomedicineHumansFemaleAnimalsNanoparticles

Stichwörter der Autor:innen

cancer therapydrug deliverysiRNAtriple-negative breast cancertumor microenvironment

Substanzen

RNA, Small Interfering

Autor:innen und Institutionen

  • Division of Breast Surgery, Department of General Surgery, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210000, People's Republic of China.
  • Key Laboratory of Advanced Organic Materials, School of Chemistry and Chemical Engineering of Nanjing University, Nanjing, Jiangsu, 210023, People's Republic of China.

Zitieren

APA

Long, Y., Yin, H., Li, J., & Zhang, W. (2026). Progress of siRNA Nanomedicines in Modulating the Microenvironment of Triple-Negative Breast Cancer. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s629428

Vancouver

Long Y, Yin H, Li J, Zhang W. Progress of siRNA Nanomedicines in Modulating the Microenvironment of Triple-Negative Breast Cancer. International Journal of Nanomedicine. 2026. doi:10.2147/ijn.s629428

BibTeX
@article{Long2026,
  author = {Long, Yongxuan and Yin, Hongyu and Li, Jinbo and Zhang, Weijie},
  title = {Progress of siRNA Nanomedicines in Modulating the Microenvironment of Triple-Negative Breast Cancer},
  journal = {International Journal of Nanomedicine},
  year = {2026},
  doi = {10.2147/ijn.s629428}
}
Kostenlos starten →